1. Introduction
Photodynamic therapy (PDT), a minimally invasive and clinically approved procedure, is used for the treatment of different types of (pre)cancers as well as certain forms of age-related macular degeneration.1,2 Three key elements are involved in PDT: a nontoxic photosensitizer (PS), light that excites the PS, and molecular oxygen. The PS, after excitation with light, can transfer some of its energy to the latter, which leads to the production of reactive oxygen species (ROS), in particular, singlet oxygen. These ROS induce cell/tissue damages, eventually resulting in cell death by apoptosis, necrosis, and/or autophagy.3–5
One of the most extensively used PS for PDT is protoporphyrin IX (PpIX). This fluorescing PS is ubiquitously present and endogenously produced in most living cells as a penultimate step in the biosynthesis of heme.6 Its production in certain cancer lesions can be significantly increased by the administration of some of its approved natural precursors, 5-aminolevulinic acid (5-ALA), or derivatives thereof. However, normal tissue inflammation, erythema, edema, pain, and/or itching have been reported as side effects of PDT.7 One of them results from the skin photosensitizations induced by sunlight when patients are treated with most of the approved PSs. These negative effects, which develop in the course of, or immediately after (hours/days) PDT, are frequently linked to the generation of ROS, especially singlet oxygen, in the normal/healthy tissues.8,9
Therefore, in this study, we have investigated the ability of catechin (Fig. 1), a natural antioxidant belonging to the family of flavonoids (polyphenols), to reduce the phototoxic effects of ROS induced by PpIX-PDT.
Flavonoids are an extensive group of polyphenolic antioxidants naturally occurring in fruits, vegetables, cocoa, chocolate, and several beverages such as wine and green tea.10–12 More precisely, catechin belongs to the family of flavanols (or flavan-3-ols), which are able to act as ROS scavengers, especially superoxide anions and singlet oxygen, thus preventing the production of free radicals.13,14
Furthermore, catechins also induce indirect antioxidant mechanisms, including the inhibition of pro-oxidant enzymes, the induction of antioxidant enzymes, and many others.15
The chicken embryo chorioallantoic membrane (CAM) has been used as an in vivo model in this study to quantify the photoprotective effects of catechin when vascular damages were induced by PpIX-PDT.
The CAM is widely used as a relevant model for studying angiogenic agents due to its developing vascular network. Indeed, the CAM plays the same role as the placenta in mammals, by supplying the nutrition and oxygen to the developing chicken embryo.16 During the embryo development, several days after the beginning of the incubation, the CAM is formed with tree-like venules and arterioles that evolve from the initial homogeneous capillary plexus.17 Its accessibility and the two-dimensional structure of the vascular network make the CAM an excellent and very convenient model for the visualization of the vascular network and, in particular, to assess the effects of PDT.
In this study, different concentrations of catechin were topically administered at different times before PpIX-PDT.
2. Material and Methods
2.1. Chemicals
All chemicals were purchased from Sigma-Aldrich, Switzerland.
2.2. CAM
Fertilized chicken eggs were purchased from Animalco AG, Switzerland. For 3 days, eggs were incubated at 37°C in a humidified and automatically rotating incubator with the blunt end up. At the embryo development day (EDD) 3, a small hole (diameter: 3 mm) was made at the pointed end of the shell and covered with tape. Afterward, eggs were placed back to the incubator in a stationary position until further use. On EDD 12, the hole was enlarged (diameter: 25 mm) enabling topical ALA and catechin administration followed by PDT.
2.3. PpIX-PDT
PpIX-based PDT has been described in detail in our previous reports.18 Briefly, ALA was dissolved in an aqueous solution of NaCl (0.9% of NaCl and 20 mg of ALA per ml with a pH of 6.8). An amount of [Formula omitted. See PDF] of this solution was topically applied on the CAM. Then, 4 h after ALA administration, PDT was conducted with the light delivered by an epifluorescent microscope (Eclipse E 600 FN Nikon) utilizing a [Formula omitted. See PDF] objective (Nikon, NA: 0.13, Plan Fluor, WD 17.1). PpIX produced endogenously was excited with light at 405 nm (filter cube BV-2A, Nikon, Japan). PpIX-PDT was performed with a light dose of [Formula omitted. See PDF] (irradiance: [Formula omitted. See PDF]). This light dose typically induces a grade 4 vascular damage according to the PDT effects scale defined by Lange et al.,19 i.e., vessels with a diameter [Formula omitted. See PDF] are all closed by PDT.
2.4. Catechin Administration
A stock solution of catechin was dissolved in EtOH before further dilution in NaCl (used for the topical administration on the CAM). Different concentrations of catechin (1, 5, 10, 20, 30, and [Formula omitted. See PDF]) were applied topically (in [Formula omitted. See PDF] of NaCl) to the CAM at different time intervals ranging between 0 and 4 h prior to PpIX-PDT. In all experiments, the content of EtOH was [Formula omitted. See PDF]. It should be noted that concentrations of catechin are relative to the weight of the embryo at given EDD, i.e., 5 g at EDD 12. For all control eggs, [Formula omitted. See PDF] of NaCl (without catechin) was topically applied on the CAM.
2.5. Angiograms Acquisition and Analysis
Fluorescent angiograms of the CAM’s vascular network were recorded 24 h after PDT. Angiograms were obtained by an intravenous injection ([Formula omitted. See PDF]) of fluorescein isothiocyanate–dextran (25 kD, 25 mg/ml) dissolved in NaCl. To further improve the contrast between the extravascular space and blood vessels of the CAM, India ink (Parker) was concurrently injected ([Formula omitted. See PDF]) under the CAM. It has been proven that India ink, which is also used as a marker for tumor margination in the human skin, is not toxic to the CAMs in our conditions.20 Angiograms were acquired with an epifluorescent microscope (Eclipse E 600 FN Nikon) utilizing a [Formula omitted. See PDF] objective (Nikon, NA: 0.13, Plan Fluor, WD 17.1). PDT potency along with the assessment of the catechin photoprotection was quantified by the quantitative analysis of these fluorescent angiograms using an ImageJ Macro (NIH, Bethesda, Maryland) developed in our laboratory.20
2.6. PpIX Photobleaching Study
Fluorescent images for this substudy have been obtained with the same microscope setup as described above. A BV-2A filter cube (excitation: 405 nm; Nikon, Japan) combined with a longpass emission filter transmitting light above 610 nm (E610LP filter; Chroma, Irvine, California) was used for PpIX fluorescence visualization and relative quantification. Images were recorded at the beginning (first 5 s) and at the end (last 5 s) of the PDT irradiations. The ImageJ software was then used to quantify the PpIX fluorescence intensity changes (at the beginning and at the end of illumination) in the presence and absence of catechin. This study was carried out with a light dose of [Formula omitted. See PDF] at 405 nm, and [Formula omitted. See PDF] catechin was administered 15 min before PDT.
3. Results and Discussion
3.1. Study of the Photoprotective Effects of Catechin Applied at Different Concentrations
As mentioned above, PpIX is one of the most frequently used PSs for PDT. Its phototoxic effects are well documented, in particular, those induced in the vascularization.18,21–23 Hence, in this study, it has been used as PS for the induction of vascular damages in the CAM. On the basis of a preliminary study, we established the spectral and radiometric conditions inducing grade 4 vascular damages according to Lange et al.19 (data not shown). We concluded that light at 405 nm applied with a dose of [Formula omitted. See PDF] and an irradiance of [Formula omitted. See PDF] was appropriate. These conditions were used in all experiments presented in Secs. 3.1 and 3.2.
In the first step, we studied the photoprotective effects of catechin applied topically at different concentrations 15 min before PDT (1 to [Formula omitted. See PDF]). Figure 2(a) shows illustrative fluorescence angiograms acquired 24 h after PDT. A quantitative analysis of fluorescence angiograms [Fig. 2(b)] to assess the efficacy of PpIX-PDT, i.e., to determine the diameter of the smallest vessels that did not close after PpIX-PDT, showed that, in the control samples, this diameter was in the order of [Formula omitted. See PDF]. On the other hand, PpIX-PDT was significantly less potent at all concentrations of catechin. More precisely, the small concentrations (1 and [Formula omitted. See PDF]) reduced the PpIX-PDT effects in such a way that the smallest vessels that did not close had an average diameter of about [Formula omitted. See PDF]. Similarly, the administration of catechin at higher concentrations (20, 30, and [Formula omitted. See PDF]) led to a reduction of the smallest not closed vessel down to 39, 47, and [Formula omitted. See PDF], respectively. An amount of [Formula omitted. See PDF] of catechin showed the most significant photoprotective effect since the average diameter of the smallest unclosed vessels was about [Formula omitted. See PDF]. It should be noted that “no light” controls (in the presence of catechin only or a combination of catechin with ALA) were conducted, resulting in an absence of vascular changes (data not shown).
Although the family of catechins is well recognized for its antioxidant properties, it should be noted that they are also able to act as pro-oxidants generating ROS.24,25 Indeed, although their antioxidant properties are due to their ability to act as free radical/ROS scavengers, their presence can stimulate hemoglobin-induced protein oxidation. This could be caused by their antioxidant capability, which promptly induces an oxidative degradation of hemoglobin,22 an effect that may explain the concentration-dependent photoprotective properties of catechin.
3.2. Determination of the Optimal Catechin Administration Time Before PpIX-PDT
Following the catechin concentration study reported in Sec. 3.1, we investigated the influence of the role played by the time separating the catechin administration and PpIX-PDT. Since [Formula omitted. See PDF] of catechin was found to be optimal, this concentration was used for the second substudy. Figure 3 shows the vascular effects of PpIX-PDT when catechin was applied topically at different times before illumination on the CAM.
We observed that the presence of [Formula omitted. See PDF] catechin reduces the PpIX-PDT effect at all times. When administered just (i.e., [Formula omitted. See PDF]) before PpIX-PDT illumination, the smallest vessel that did not close was in the order of [Formula omitted. See PDF]. Increasing the time between catechin administration and illumination up to about 15 min led to more potent inhibitions of the vascular effects of PpIX-PDT. Indeed, when catechin was applied 7 min before PDT, the average diameter of the smallest unclosed vessel was [Formula omitted. See PDF], whereas this diameter went down to [Formula omitted. See PDF] at the optimal time of 15 min. With longer times (30 min and more), catechin became less and less potent to generate a photoprotection.
According to our knowledge, there is no literature on the catechin pharmacokinetics in the CAM. However, studies conducted on rodents, dogs, rabbits, and humans showed that, after oral administration, catechin is mainly metabolized by phase-2 conjugation process in the liver and intestine.26 In our study conducted on the CAM, the reduced photoprotection observed at times [Formula omitted. See PDF] could be explained by the catechin internalization by the CAM and chicken embryo itself.
3.3. Assessment of the ROS Production During PDT Based on the Measurement of the PpIX Fluorescence Photobleaching
Measurements conducted in this part of the study were based on the observation that PpIX photobleaches during PDT, an effect that is directly related to the ROS (mostly singlet oxygen) production.27 Indeed, Moan and Berg28 demonstrated that the more ROS are created, the more PpIX is photobleached. Therefore, it is of interest to determine if a correlation exists between the photoprotective effects of catechin and the PpIX photobleaching. Thus, this estimation of the protective effect of catechin was compared with its ability to prevent photobleaching of PpIX. Figure 4 shows the ratio of the fluorescence intensity of PpIX measured at the beginning (first 5 s) divided by this intensity measured at the end of PDT (last 5 s), both for a control group (no catechin) and in the presence of [Formula omitted. See PDF] catechin applied 15 min before PpIX-PDT. If no photobleaching would occur, the ratio of the PpIX fluorescence at the beginning and at the end of illumination would be equal to 1.
For the purpose of acquiring a good signal-to-noise ratio, the light dose used for this part of the study was increased to [Formula omitted. See PDF] for all conditions (controls and [Formula omitted. See PDF] catechin). It should be noted that increasing the light dose did not preclude the photoprotective effect of catechin. At the same time, it is interesting to point out that when photobleaching experiments of PpIX were conducted with [Formula omitted. See PDF] (see Secs. 3.1 and 3.2), the PpIX photobleaching was almost not measurable (data not showed), although the tissue damages were significant. On the whole, these observations suggest that only a small fraction of the PpIX present on the CAM membrane 4 h after ALA application is actually localized in compartment(s), probably the mitochondria, playing a crucial role in the photosensitization process. This suggests that the majority of the PpIX fluorescing in the CAM in our conditions plays a reduced role in the photosensitization process, if any, probably because it is outside these critical compartments.
Nevertheless, as shown in Fig. 4, [Formula omitted. See PDF] catechin not only reduces the PpIX photobleaching, but leads to an increase of the PpIX fluorescence in the CAM. This effect is probably due, at least in part, to the ability of catechin to reduce the ROS concentration. It could also be that the increase of PpIX fluorescence observed during PDT in the presence of catechin is due to a chelation of iron by this flavanol, as postulated by Samman et al.29 This mechanism may impair the availability of iron to convert PpIX in heme, thus leading to an increase of the PpIX fluorescence detected in the CAM.
4. Conclusion
It is well known that patients treated by PDT often suffer from skin photosensitization. In addition, those patients subject to radiotherapies frequently experience damages in various organs, including the skin, as a consequence of the ROS production in the tissues. Since the family of catechins is well known for its antioxidant properties, we investigated if its topical application could induce photoprotective effects in normal tissues during PpIX-PDT and/or if it could be used to protect the skin of patients against photosensitization induced by PpIX-PDT. The influence of the catechin concentration and the time between its administration and PpIX-PDT were studied on the CAM vascularization. We observed that catechin reduced the PpIX-PDT potency in all conditions we explored, whereby [Formula omitted. See PDF] catechin administered topically 15 min before PDT had the most potent photoprotective effect. In addition, we demonstrated that, in these conditions, catechin diminishes the PpIX photobleaching induced by PpIX-PDT. Although additional experiments exploring other administration conditions carried out on different model systems are necessary, our results suggest that catechin is an interesting candidate to protect normal tissues during PDT or radiotherapy.
Disclosure
Authors have no conflicts of interest to declare.
Acknowledgments
The authors are grateful for the financial support of AC BioScience and the Swiss National Science Foundation (project 315230_185262/1).
Biographies of the authors are not available.
1. H. van den Bergh, “Photodynamic therapy of age-related macular degeneration: history and principles,” Semin. Ophthalmol., 16 (4), 181 –200 (2001). https://doi.org/10.1076/soph.16.4.181.10299 SEOPE7
2. H. van den Bergh, J.-P. Ballini and M. Sickenberg, “On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration,” J. Fr. Ophtalmol., 27 (1), 75 –78 (2004). https://doi.org/10.1016/S0181-5512(04)96097-4
3. C. Fleury, B. Mignotte and J.-L. Vayssière, “Mitochondrial reactive oxygen species in cell death signaling,” Biochimie, 84 (2–3), 131 –141 (2002). https://doi.org/10.1016/S0300-9084(02)01369-X BICMBE 0300-9084
4. M. Redza-Dutordoir and D. A. Averill-Bates, “Activation of apoptosis signalling pathways by reactive oxygen species,” Biochim. Biophys. Acta, Mol. Cell Res., 1863 (12), 2977 –2992 (2016). https://doi.org/10.1016/j.bbamcr.2016.09.012
5. M. B. Azad, Y. Chen and S. B. Gibson, “Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment,” Antioxid. Redox. Signal., 11 (4), 777 –790 (2009). https://doi.org/10.1089/ars.2008.2270
6. M. Sachar, K. E. Anderson and X. Ma, “Protoporphyrin IX: the good, the bad, and the ugly,” J. Pharmacol. Exp. Ther., 356 (2), 267 –275 (2016). https://doi.org/10.1124/jpet.115.228130 JPETAB 0022-3565
7. F. Borgia et al., “Early and late onset side effects of photodynamic therapy,” Biomedicines, 6 (1), 12 (2018). https://doi.org/10.3390/biomedicines6010012
8. M. C. DeRosa and R. J. Crutchley, “Photosensitized singlet oxygen and its applications,” Coord. Chem. Rev., 233–234 351 –371 (2002). https://doi.org/10.1016/S0010-8545(02)00034-6 CCHRAM 0010-8545
9. J. M. Dąbrowski, “Reactive oxygen species in photodynamic therapy: mechanisms of their generation and potentiation,” Advances in Inorganic Chemistry, 70 343 –394 Academic Press(2017).
10. M. G. Hertog et al., “Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study,” Lancet, 342 (8878), 1007 –1011 (1993). https://doi.org/10.1016/0140-6736(93)92876-U LANCAO 0140-6736
11. J. Kühnau, “The flavonoids. A class of semi-essential food components: their role in human nutrition,” World Rev. Nutr. Diet., 24 117 –191 (1976).
12. J. Allgrove, G. Davison, “Dark chocolate/cocoa polyphenols and oxidative stress,” Polyphenols in Human Health and Disease, 241 –251 Academic Press, San Diego (2014).
13. S. Rafat Husain, J. Cillard and P. Cillard, “Hydroxyl radical scavenging activity of flavonoids,” Phytochemistry, 26 (9), 2489 –2491 (1987). https://doi.org/10.1016/S0031-9422(00)83860-1 PYTCAS
14. C. G. Fraga et al., “Basic biochemical mechanisms behind the health benefits of polyphenols,” Mol. Aspects Med., 31 (6), 435 –445 (2010). https://doi.org/10.1016/j.mam.2010.09.006
15. J. Bernatoniene and D. M. Kopustinskiene, “The role of catechins in cellular responses to oxidative stress,” Molecules, 23 (4), 965 (2018). https://doi.org/10.3390/molecules23040965
16. V. G. Djonov, H. Kurz and P. H. Burri, “Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism,” Dev. Dyn., 224 (4), 391 –402 (2002). https://doi.org/10.1002/dvdy.10119
17. A. F. Smith et al., “Microvascular hemodynamics in the chick chorioallantoic membrane,” Microcirculation, 23 (7), 512 –522 (2016). https://doi.org/10.1111/micc.12301 MCCRD8 0275-4177
18. F. Piffaretti et al., “Real-time, in vivo measurement of tissular pO2 through the delayed fluorescence of endogenous protoporphyrin IX during photodynamic therapy,” J. Biomed. Opt., 17 (11), 115007 (2012). https://doi.org/10.1117/1.JBO.17.11.115007 JBOPFO 1083-3668
19. N. Lange et al., “A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV,” Invest. Ophthalmol. Vis. Sci., 42 (1), 38 –46 (2001). IOVSDA 0146-0404
20. P. Nowak-Sliwinska et al., “Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model,” Microvasc. Res., 79 (1), 21 –28 (2010). https://doi.org/10.1016/j.mvr.2009.10.004 MIVRA6 0026-2862
21. C. J. Fisher et al., “ALA-PpIX mediated photodynamic therapy of malignant gliomas augmented by hypothermia,” PLoS One, 12 (7), e0181654 (2017). https://doi.org/10.1371/journal.pone.0181654 POLNCL 1932-6203
22. M. B. Ericson, A.-M. Wennberg and O. Larkö, “Review of photodynamic therapy in actinic keratosis and basal cell carcinoma,” Ther. Clin. Risk Manage., 4 (1), 1 –9 (2008).
23. M. Goldman and D. Atkin, “ALA/PDT in the treatment of actinic keratosis: spot versus confluent therapy,” J. Cosmet. Laser Ther., 5 107 –110 (2003). https://doi.org/10.1080/14769170310001267
24. C. S. Yang et al., “Effects of tea catechins on cancer signaling pathways,” Enzymes, 36 195 –221 (2014). https://doi.org/10.1016/B978-0-12-802215-3.00010-0
25. J. D. Lambert and R. J. Elias, “The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention,” Arch. Biochem. Biophys., 501 65 –72 (2010). https://doi.org/10.1016/j.abb.2010.06.013
26. K. O. Chu, C. C. P. Pang, “Pharmacokinetics and disposition of green tea catechins,” Pharmacokinetics and Adverse Effects of Drugs: Mechanisms and Risks Factors, 2018).
27. G. S. Cox, C. Bobillier and D. G. Whitten, “Photooxidation and singlet oxygen sensitization by protoporphyrin IX and its photooxidation products,” Photochem. Photobiol., 36 (4), 401 –407 (1982). https://doi.org/10.1111/php.1982.36.issue-4 PHCBAP 0031-8655
28. J. Moan and K. Berg, “The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen,” Photochem. Photobiol., 53 (4), 549 –553 (1991). https://doi.org/10.1111/php.1991.53.issue-4 PHCBAP 0031-8655
29. S. Samman et al., “Green tea or rosemary extract added to foods reduces nonheme-iron absorption,” Am. J. Clin. Nutr., 73 (3), 607 –612 (2001). https://doi.org/10.1093/ajcn/73.3.607
Jaroslava Joniová,1 Georges Wagnières1
1Ecole Polytechnique Fédérale de Lausanne (Switzerland)
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2020. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Significance: Side effects of many cancer treatments are associated with the production of reactive oxygen species (ROS) in normal tissues. This explains why patients treated by photodynamic therapy (PDT) often suffer from skin photosensitization, whereas those subject to radiotherapies frequently experience damages in various organs, including the skin.
Aim: Catechin, which belongs to the natural flavanols family, is well known for its antioxidant properties. Hence, our main objective was to investigate whether catechin can reduce damages induced by PDT using protoporphyrin IX (PpIX-PDT), an endogenous photosensitizer commonly used in dermatology.
Approach: An in vivo model, the chick embryo chorioallantoic membrane (CAM), was used for this study. An amount of 20 μl of a solution containing 5-aminolevulinic acid, a natural precursor of PpIX, was applied topically on the CAM 4 h before PDTs (405 nm, 2.9 mW / cm2, 1.2 J / cm2). Catechin was applied at different concentrations (1 to 50 μM) and times (0 to 240 min) before PDT. In addition, we assessed the potency of catechin to reduce the PpIX fluorescence photobleaching induced by PDT.
Results: We observed that catechin significantly reduces the vascular damages generated by PpIX-PDT. Moreover, we have shown that catechin inhibits PpIX photobleaching.
Conclusions: These observations suggest that catechin significantly reduces the level of ROS produced by PpIX-PDT.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer